Literature DB >> 21228243

Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway.

Giulia Fabozzi1, Christopher S Nabel, Michael A Dolan, Nancy J Sullivan.   

Abstract

Cellular RNA interference (RNAi) provides a natural response against viral infection, but some viruses have evolved mechanisms to antagonize this form of antiviral immunity. To determine whether Ebolavirus (EBOV) counters RNAi by encoding suppressors of RNA silencing (SRSs), we screened all EBOV proteins using an RNAi assay initiated by exogenously delivered small interfering RNAs (siRNAs) against either an EBOV or a reporter gene. In addition to viral protein 35 (VP35), we found that VP30 and VP40 independently act as SRSs. Here, we present the molecular mechanisms of VP30 and VP35. VP30 interacts with Dicer independently of siRNA and with one Dicer partner, TRBP, only in the presence of siRNA. VP35 directly interacts with Dicer partners TRBP and PACT in an siRNA-independent fashion and in the absence of effects on interferon (IFN). Taken together, our findings elucidate a new mechanism of RNAi suppression that extends beyond the role of SRSs in double-stranded RNA (dsRNA) binding and IFN antagonism. The presence of three suppressors highlights the relevance of host RNAi-dependent antiviral immunity in EBOV infection and illustrates the importance of RNAi in shaping the evolution of RNA viruses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228243      PMCID: PMC3067942          DOI: 10.1128/JVI.01160-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

Review 1.  NPS@: network protein sequence analysis.

Authors:  C Combet; C Blanchet; C Geourjon; G Deléage
Journal:  Trends Biochem Sci       Date:  2000-03       Impact factor: 13.807

Review 2.  To kill or be killed: viral evasion of apoptosis.

Authors:  Chris A Benedict; Paula S Norris; Carl F Ware
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Characterization of the interactions between mammalian PAZ PIWI domain proteins and Dicer.

Authors:  Nasser Tahbaz; Fabrice A Kolb; Haidi Zhang; Katarzyna Jaronczyk; Witold Filipowicz; Tom C Hobman
Journal:  EMBO Rep       Date:  2004-01-16       Impact factor: 8.807

4.  Human RISC couples microRNA biogenesis and posttranscriptional gene silencing.

Authors:  Richard I Gregory; Thimmaiah P Chendrimada; Neil Cooch; Ramin Shiekhattar
Journal:  Cell       Date:  2005-11-03       Impact factor: 41.582

5.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

6.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

7.  Induction and suppression of RNA silencing by an animal virus.

Authors:  Hongwei Li; Wan Xiang Li; Shou Wei Ding
Journal:  Science       Date:  2002-05-17       Impact factor: 47.728

8.  RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription.

Authors:  Qing Ge; Michael T McManus; Tam Nguyen; Ching-Hung Shen; Phillip A Sharp; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-19       Impact factor: 11.205

9.  Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing.

Authors:  Wan-Xiang Li; Hongwei Li; Rui Lu; Feng Li; Monica Dus; Peter Atkinson; Edward W A Brydon; Kyle L Johnson; Adolfo García-Sastre; L Andrew Ball; Peter Palese; Shou-Wei Ding
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

10.  Interference of hepatitis C virus RNA replication by short interfering RNAs.

Authors:  Sharookh B Kapadia; Amy Brideau-Andersen; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-03       Impact factor: 11.205

View more
  70 in total

1.  Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences.

Authors:  John Misasi; Kartik Chandran; Jin-Yi Yang; Bryden Considine; Claire Marie Filone; Marceline Côté; Nancy Sullivan; Giulia Fabozzi; Lisa Hensley; James Cunningham
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Authors:  Sylvanne M Daniels; Lucile Sinck; Natalie J Ward; Carlos E Melendez-Peña; Robert J Scarborough; Ibrahim Azar; Elodie Rance; Aïcha Daher; Ka-Ming Pang; John J Rossi; Anne Gatignol
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

3.  RNA interference functions as an antiviral immunity mechanism in mammals.

Authors:  Yang Li; Jinfeng Lu; Yanhong Han; Xiaoxu Fan; Shou-Wei Ding
Journal:  Science       Date:  2013-10-11       Impact factor: 47.728

4.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

5.  The Mammalian response to virus infection is independent of small RNA silencing.

Authors:  Simone Backes; Ryan A Langlois; Sonja Schmid; Andrew Varble; Jaehee V Shim; David Sachs; Benjamin R tenOever
Journal:  Cell Rep       Date:  2014-06-19       Impact factor: 9.423

Review 6.  Innate immune evasion by filoviruses.

Authors:  Christopher F Basler
Journal:  Virology       Date:  2015-04-03       Impact factor: 3.616

Review 7.  Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells.

Authors:  Victoria Lm Herrera; Aaron H Colby; Nelson Ruiz-Opazo; David G Coleman; Mark W Grinstaff
Journal:  Nanomedicine (Lond)       Date:  2018-09-11       Impact factor: 5.307

8.  Ebola Virus Produces Discrete Small Noncoding RNAs Independently of the Host MicroRNA Pathway Which Lack RNA Interference Activity in Bat and Human Cells.

Authors:  Abhishek N Prasad; Adam J Ronk; Steven G Widen; Thomas G Wood; Christopher F Basler; Alexander Bukreyev
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

9.  Could the Ebola virus matrix protein VP40 be a drug target?

Authors:  Robert V Stahelin
Journal:  Expert Opin Ther Targets       Date:  2013-11-28       Impact factor: 6.902

10.  The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Authors:  Martina Trunschke; Dominik Conrad; Sven Enterlein; Judith Olejnik; Kristina Brauburger; Elke Mühlberger
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.